Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 4/2015

01-11-2015

Preferences for anticoagulation therapy in atrial fibrillation: the patients’ view

Authors: Björn Böttger, Inga-Marion Thate-Waschke, Rupert Bauersachs, Thomas Kohlmann, Thomas Wilke

Published in: Journal of Thrombosis and Thrombolysis | Issue 4/2015

Login to get access

Abstract

Since the introduction of new oral anticoagulants (NOACs), besides vitamin-K antagonists, an additional option for stroke prevention of patients with atrial fibrillation (AF) is available. The objective of this study was to assess AF patients’ preferences with regard to the attributes of these different treatment options. We conducted a multicenter study among randomly selected physicians. Preferences were assessed by computer-assisted telephone interviews. We used a discrete-choice-experiment (DCE) with four convenience-related treatment dependent attributes (need of bridging: yes/no, interactions with food/nutrition: yes/no, need of INR controls/dose adjustment: yes/no; frequency of intake: once/twice daily) and one comparator attribute (distance to practitioner: <1 km/>15 km). Preferences measured in the interviews were analyzed descriptively and based on a conditional logit regression model. A total of 486 AF patients (age: 73.9 ± 8.2 years; 43.2 % female; mean CHA2DS2-VASc: 3.7 ± 1.6; current medication: 48.1 % rivaroxaban, 51.9 % VKA) could be interviewed. Regardless of type of medication, patients significantly preferred the attribute levels (in order of patients’ importance) “once daily intake” (Level: once = 1 vs. twice = 0; Coefficient = 0.615; p < 0.001), “bridging necessary” (yes = 1 vs. no = 0; −0.558; p < 0.001), “distance to practitioner of ≤1 km (>15 km = 0 vs. ≤1 km = 1; 0.494; p < 0.001), “interactions with food/nutrition” (yes = 1 vs. no = 0; −0.332; p < 0.001) and “need of INR controls/dose adjustment” (yes = 1 vs. no = 0; −0.127; p < 0.001). In our analyses, “once daily frequency of intake” was the most important OAC-attribute for patients’ choice followed by “no bridging necessary” and “no interactions with food/nutrition”. Thus, patients with AF seem to prefer treatment options which are easier to administer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ryder KM, Benjamin EJ (1999) Epidemiology and significance of atrial fibrillation. Am J Cardiol 84(9A):131R–138RCrossRefPubMed Ryder KM, Benjamin EJ (1999) Epidemiology and significance of atrial fibrillation. Am J Cardiol 84(9A):131R–138RCrossRefPubMed
2.
go back to reference Chugh SS, Blackshear JL, Shen WK et al (2001) Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 37(2):371–378CrossRefPubMed Chugh SS, Blackshear JL, Shen WK et al (2001) Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 37(2):371–378CrossRefPubMed
3.
go back to reference Chien KL, Su TC, Hsu HC et al (2010) Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese. Int J Cardiol 139(2):173–180CrossRefPubMed Chien KL, Su TC, Hsu HC et al (2010) Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese. Int J Cardiol 139(2):173–180CrossRefPubMed
4.
go back to reference Fang MC, Go AS, Chang Y et al (2008) ATRIA Study Group. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 51(8):810–815PubMedCentralCrossRefPubMed Fang MC, Go AS, Chang Y et al (2008) ATRIA Study Group. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 51(8):810–815PubMedCentralCrossRefPubMed
5.
go back to reference Wilke T, Groth A, Mueller S et al (2013) Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace 15(4):486–493CrossRefPubMed Wilke T, Groth A, Mueller S et al (2013) Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace 15(4):486–493CrossRefPubMed
6.
go back to reference Davis RC, Hobbs FD, Kenkre JE et al (2012) Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. Europace 14:1553–1559CrossRefPubMed Davis RC, Hobbs FD, Kenkre JE et al (2012) Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. Europace 14:1553–1559CrossRefPubMed
7.
go back to reference Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369–2429CrossRefPubMed Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369–2429CrossRefPubMed
8.
go back to reference Kirchhof P, Auricchio A, Bax J et al (2007) Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 28:2803–2817CrossRefPubMed Kirchhof P, Auricchio A, Bax J et al (2007) Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 28:2803–2817CrossRefPubMed
9.
go back to reference Stewart S, Hart CL, Hole DJ et al (2002) A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 113:359–364CrossRefPubMed Stewart S, Hart CL, Hole DJ et al (2002) A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 113:359–364CrossRefPubMed
10.
go back to reference Friberg L, Hammar N, Rosenqvist M (2010) Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J 31:967–975CrossRefPubMed Friberg L, Hammar N, Rosenqvist M (2010) Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J 31:967–975CrossRefPubMed
11.
go back to reference Halperin JL, Kay GN, Le Huezey JY et al (2011) ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 123:e269–e367CrossRefPubMed Halperin JL, Kay GN, Le Huezey JY et al (2011) ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 123:e269–e367CrossRefPubMed
12.
go back to reference Gage BF, Waterman AD, Shannon W et al (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285(22):2864–2870CrossRefPubMed Gage BF, Waterman AD, Shannon W et al (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285(22):2864–2870CrossRefPubMed
13.
go back to reference Lip GY, Nieuwlaat R, Pisters R et al (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 137:263–272CrossRefPubMed Lip GY, Nieuwlaat R, Pisters R et al (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 137:263–272CrossRefPubMed
14.
go back to reference Fumagalli S, Cardini F, Roberts AT et al (2014) Psychological effects of treatment with new oral anticoagulants in elderly patients with atrial fibrillation: a preliminary report. Aging Clin Exp Res Fumagalli S, Cardini F, Roberts AT et al (2014) Psychological effects of treatment with new oral anticoagulants in elderly patients with atrial fibrillation: a preliminary report. Aging Clin Exp Res
15.
go back to reference Ogilvie IM, Newton N, Welner SA et al (2010) Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 123(7):638–645CrossRefPubMed Ogilvie IM, Newton N, Welner SA et al (2010) Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 123(7):638–645CrossRefPubMed
16.
go back to reference Wilke T, Groth A, Pfannkuche M et al (2014) Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use. J Thromb Thrombol Wilke T, Groth A, Pfannkuche M et al (2014) Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use. J Thromb Thrombol
17.
go back to reference Wilke T, Groth A, Mueller S et al (2012) Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost 107(6):1053–1065CrossRefPubMed Wilke T, Groth A, Mueller S et al (2012) Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost 107(6):1053–1065CrossRefPubMed
18.
go back to reference Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151CrossRefPubMed Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151CrossRefPubMed
19.
go back to reference Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891CrossRefPubMed Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891CrossRefPubMed
20.
go back to reference Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992CrossRefPubMed Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992CrossRefPubMed
21.
go back to reference Ghijben P, Lancsar E, Zavarsek S (2014) Preferences for oral anticoagulants in atrial fibrillation: a best-best discrete choice experiment. Pharmacoeconomics 32(11):1115–1127CrossRefPubMed Ghijben P, Lancsar E, Zavarsek S (2014) Preferences for oral anticoagulants in atrial fibrillation: a best-best discrete choice experiment. Pharmacoeconomics 32(11):1115–1127CrossRefPubMed
22.
go back to reference Bakhai A, Sandberg A, Mittendorf T et al (2013) Patient perspective on the management of atrial fibrillation in five European countries. BMC Cardiovasc Disord 13:108PubMedCentralCrossRefPubMed Bakhai A, Sandberg A, Mittendorf T et al (2013) Patient perspective on the management of atrial fibrillation in five European countries. BMC Cardiovasc Disord 13:108PubMedCentralCrossRefPubMed
23.
go back to reference Jones C, Pollit V, Fitzmaurice D et al (2014) The management of atrial fibrillation: summary of updated NICE guidance. BMJ 348:g3655CrossRefPubMed Jones C, Pollit V, Fitzmaurice D et al (2014) The management of atrial fibrillation: summary of updated NICE guidance. BMJ 348:g3655CrossRefPubMed
24.
go back to reference Man-Son-Hing M, Gage BF, Montgomery AA et al (2005) Preference-based antithrombotic therapy in atrial fibrillation: implications for clinical decision making. Med Decis Making 25(5):548–559CrossRefPubMed Man-Son-Hing M, Gage BF, Montgomery AA et al (2005) Preference-based antithrombotic therapy in atrial fibrillation: implications for clinical decision making. Med Decis Making 25(5):548–559CrossRefPubMed
25.
go back to reference Gage BF, Cardinalli AB, Owens DK (1998) Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke 29(6):1083–1091CrossRefPubMed Gage BF, Cardinalli AB, Owens DK (1998) Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke 29(6):1083–1091CrossRefPubMed
26.
go back to reference Protheroe J, Fahey T, Montgomery AA et al (2000) The impact of patients’ preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ 320(7246):1380–1384PubMedCentralCrossRefPubMed Protheroe J, Fahey T, Montgomery AA et al (2000) The impact of patients’ preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ 320(7246):1380–1384PubMedCentralCrossRefPubMed
27.
go back to reference Johnson RF, Orme BK (2010) Sample size issues for conjoint analysis. Orme BK, Getting started with conjoint analysis: strategies for product design and pricing research. Research Publishers, Madison, pp 57–66 Johnson RF, Orme BK (2010) Sample size issues for conjoint analysis. Orme BK, Getting started with conjoint analysis: strategies for product design and pricing research. Research Publishers, Madison, pp 57–66
28.
go back to reference Ware JE, Kosinski M, Keller SD (1996) A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 34(3):220–233CrossRefPubMed Ware JE, Kosinski M, Keller SD (1996) A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 34(3):220–233CrossRefPubMed
29.
go back to reference Clark MD, Determann D, Petrou S et al (2014) Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics 32(9):883–902CrossRefPubMed Clark MD, Determann D, Petrou S et al (2014) Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics 32(9):883–902CrossRefPubMed
30.
go back to reference Reed Johnson F, Lancsar E, Marshall D et al (2013) Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health 16(1):3–13CrossRefPubMed Reed Johnson F, Lancsar E, Marshall D et al (2013) Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health 16(1):3–13CrossRefPubMed
33.
go back to reference MacLean S, Mulla S, Akl EA et al (2012) Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e1S–e23SPubMedCentralPubMed MacLean S, Mulla S, Akl EA et al (2012) Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e1S–e23SPubMedCentralPubMed
34.
go back to reference Moia M, Mantovani LG, Carpenedo M et al (2013) Patient preferences and willingness to pay for different options of anticoagulant therapy. Intern Emerg Med 8(3):237–243CrossRefPubMed Moia M, Mantovani LG, Carpenedo M et al (2013) Patient preferences and willingness to pay for different options of anticoagulant therapy. Intern Emerg Med 8(3):237–243CrossRefPubMed
35.
go back to reference Borg Xuereb C, Shaw RL, Lane DA (2012) Patients’ and health professionals’ views and experiences of atrial fibrillation and oral-anticoagulant therapy: a qualitative meta-synthesis. Patient Educ Couns 88(2):330–337CrossRefPubMed Borg Xuereb C, Shaw RL, Lane DA (2012) Patients’ and health professionals’ views and experiences of atrial fibrillation and oral-anticoagulant therapy: a qualitative meta-synthesis. Patient Educ Couns 88(2):330–337CrossRefPubMed
36.
go back to reference Coleman CI, Roberts MS, Sobieraj DM et al (2012) Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin 28(5):669–680CrossRefPubMed Coleman CI, Roberts MS, Sobieraj DM et al (2012) Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin 28(5):669–680CrossRefPubMed
37.
go back to reference Choi JC, Dibonaventura MD, Kopenhafer L et al (2014) Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation. Patient Prefer Adherence 8:167–177PubMedCentralPubMed Choi JC, Dibonaventura MD, Kopenhafer L et al (2014) Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation. Patient Prefer Adherence 8:167–177PubMedCentralPubMed
38.
go back to reference Palacio AM, Kirolos I, Tamariz L (2015) Patient values and preferences when choosing anticoagulants. Patient Prefer Adherence 9:133–138PubMedCentralPubMed Palacio AM, Kirolos I, Tamariz L (2015) Patient values and preferences when choosing anticoagulants. Patient Prefer Adherence 9:133–138PubMedCentralPubMed
Metadata
Title
Preferences for anticoagulation therapy in atrial fibrillation: the patients’ view
Authors
Björn Böttger
Inga-Marion Thate-Waschke
Rupert Bauersachs
Thomas Kohlmann
Thomas Wilke
Publication date
01-11-2015
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 4/2015
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-015-1263-x

Other articles of this Issue 4/2015

Journal of Thrombosis and Thrombolysis 4/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.